Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of “patented” ATO is prohibitive because of patent rights. “Generic” ATO has been used in a few countries, but its implic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Bankar, Aniket, Korula, Anu, Kulkarni, Uday P., Devasia, Anup J., Fouzia, NA, Lionel, Sharon, Abraham, Aby, Balasubramanian, Poonkuzhali, Janet, Nancy Beryl, Nair, Sukesh C., Sezlian, S, Jeyaseelan, Visali, Jeyaseelan, N, Prasad, Jasmine, George, Biju, Mathews, Vikram
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7617145/
https://ncbi.nlm.nih.gov/pubmed/31863602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16343
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados